The company develops antibody-based treatments for cancer and infectious diseases by discovering the most effective antibodies from individuals who have overcome disease or from immunised animals. AIMM Therapeutics' human monoclonal antibodies and antibody discovery platform use proprietary knowledge of B cell immortalisation to isolate promising antibodies from humans or animals, providing healthcare organisations with cost-efficient, quality care for patients.